Citations

Clear

30 citation(s) found for "Chung, Ji Young".

Abstract 3751: QVT Subscore: An interpretable radiomic panel of tumor vascularity reveals treatment-specific mechanisms-of-action (MoA) in NSCLC
Li, Haojia, Mutha, P., Chae, Young Kwang , Zhang, Kai, Chung, Liam Il‐Young , Hiremath, Amogh , Chitalia, Rhea , Yau, Justin, Haji-Maghsoudi, Omid, Arul, Trishan, Velcheti, Vamsidhar, Madabhushi, Anant, Li, Haojia, Mutha, Pushkar , Maghsoudi, Omid Haji , Arul, Trishan, Velcheti, Vamsidhar, Braman, Nathaniel

Mayo Clinic

Cancer Research | April 3, 2026 | Volume: 86 | Issue: 7_Supplement | Pages: 3751-3751

10.1158/1538-7445.am2026-3751 Get It

Abstract Background: Tumor angiogenesis drives treatment resistance by fostering an immunosuppressive microenvironment. VEGF inhibitors (VEGFi) target the vasculature, while immune checkpoint inhibitors (ICI) do not address this mechanism directly. Quantitative Vessel Tortuosity (QVT) Score is a radiomic biomarker of vascularity previously shown to be associated with ICI response. Here, we introduce QVT Subscore, an interpretable panel that isolates distinct vascular attributes (e.g., branching, curvature, radius), enabling treatment-specific insight into vascularity MoA and vascular normalization. Methods: QVT Subscores are derived by grouping the 910 QVT features comprising QVT Score into six biological categories, summarized by principal component analysis. The panel was evaluated in 557 patients from the phase 3 SWOG S0819 trial and a real-world ICI monotherapy cohort (n=147). QVT score/subscore changes from baseline to first on-treatment CTs were assessed by paired t-test and substratified by objective response (OR). Results: While the mono-chemotherapy showed no vascularity changes, VEGFi regimens reduced QVT Score, with Branch and Curvature Subscores decreasing significantly but Vessel Volume unchanged. In contrast, ICI recipients exhibited significant increases in QVT Score and 5/6 Subscores, showing opposite changes to VEGFi in four subscores and differing effects on vessel Radius and Volume. VEGFi produced the greatest vascularity decrease in patients achieving OR, with milder decreases in non-OR. For ICI, OR showed negligible QVT change, while vascularity significantly increased in non-OR across all subscores except Radius. Conclusions: The QVT Subscore panel captures granular tumor vascular remodeling from different treatments, providing mechanistically grounded insights into clinical trial arm performance. Future work will assess the panel’s potential for identifying regimens that benefit from adding VEGFi. Citation Format: Haojia Li, Pushkar Mutha, Young Kwang Chae, Kai Zhang, Liam Il-Young Chung, Amogh Hiremath, Rhea Chitalia, Justin Yau, Omid Haji-Maghsoudi, Trishan Arul, Vamsidhar Velcheti, Anant Madabhushi, Nathaniel Braman. QVT Subscore: An interpretable radiomic panel of tumor vascularity reveals treatment-specific mechanisms-of-action (MoA) in NSCLC [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2026; Part 1 (Regular Abstracts); 2026 Apr 17-22; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2026;86(7 Suppl):Abstract nr 3751.
QVT score, a radiomic biomarker of vascular complexity, enables prognostication and monitoring of NSCLC immunotherapy
Chae, Young Kwang , Velcheti, Vamsidhar, Zhang, Kai , Hiremath, Amogh , Chung, Liam Il‐Young , Haji-Maghsoudi, Omid, Chitalia, Rhea , Lee, Jeeyeon, Li, Haojia, Mutha, Pushkar , Nagabhushan, Rushil, Levy, David, Cantor, Diego, Kim, Yuchan, Cheung, Trevor , Kim, Haseok, Gupta, Amit, Arul, Trishan, Madabhushi, Anant, Braman, Nathaniel , Madabhushi, Anant , Braman, Nathaniel , Velcheti, Vamsidhar, Maghsoudi, Omid Haji , Lee, Seyoung , Kim, Yuchan, Arul, Trishan, Madabhushi, Anant

Mayo Clinic

Journal for ImmunoTherapy of Cancer | February 20, 2026 | Volume: 14 | Issue: 2 | Pages: e013391

10.1136/jitc-2025-013391 | PMID 41720608 Get It

Background Immune checkpoint inhibitors (ICIs) improve survival in advanced non-small cell lung cancer (NSCLC), yet current biomarkers such as programmed death-ligand 1 (PD-L1) expression and response criteria (Response Evaluation Criteria in Solid Tumors, RECIST, V.1.1) align poorly with long-term survival. Radiomics has been proposed as a source of novel biomarkers, but standard radiomic approaches suffer from limited biological interpretability and poor generalizability across treatment settings. We address these gaps by developing the Quantitative Vessel Tortuosity (QVT) score, a biologically interpretable imaging biomarker that quantifies tumor vascular complexity—a known mediator of immune evasion—from routine imaging. We hypothesized that QVT score would improve prognostication and enable treatment response monitoring in ICI-treated NSCLC, independent of current biomarkers. Methods This retrospective, multicenter study analyzed 1,301 CT scans from 682 patients with ICI-treated NSCLC. An automated pipeline segmented lesions and tumor-associated vasculature within each scan, extracting 910 QVT features measuring vascular shape and complexity. Unsupervised clustering of these features in a discovery cohort (N=375) was performed to identify fundamental vascular phenotypes. A continuous QVT score was then derived using regularized logistic regression to map patients along this phenotypic spectrum. QVT score was externally validated in ICI monotherapy (N=172) and chemoimmunotherapy (N=135) cohorts. In a longitudinal cohort (n=143), early on-treatment QVT score changes were evaluated for overall survival (OS) association. Results Two robust vascular phenotypes emerged in the discovery cohort: a highly vascularized, chaotic “QVT High” phenotype with poor post-ICI OS and a “QVT Low” phenotype with normalized vasculature and improved ICI outcomes. The continuous QVT score was prognostic for ICI monotherapy (HR=1.17 per 0.1 increase, p=0.0028) and chemoimmunotherapy (HR = 1.23 per 0.1 increase, p = 4.9×10⁻⁵). High QVT status remained prognostic for both treatments after adjustment for PD-L1 and clinical variables (adjusted HR range: 2.13–2.38, p≤0.002). Early decreases in QVT score during therapy, indicating vascular normalization, were associated with improved OS (HR=1.93, p=0.0022) independent of RECIST best overall response and tumor volume change. Conclusions QVT score is a novel, biologically interpretable imaging biomarker that quantifies vascular complexity. It enables automated, non-invasive prediction and monitoring of ICI outcomes by capturing treatment-induced vascular remodeling. Integrating QVT score into clinical decision-making and drug development can address critical gaps in precision oncology.
RSV Vaccine with Nanoparticle-Based Poly-Sorbitol Transporter (PST) Adjuvant Improves Respiratory Protection Against RSV Through Inducing Both Systemic and Mucosal Humoral Immunity
Jung, Seong-Mook , Park, Young Chae, Seo, Eun Suk, Kim, Cheol Gyun , Kim, Taewoo , Yun, Cheol‐Heui , Shim, Byoung-Shik, Cheon, In Su , Son, Young Min , Yun, Cheol-Heui , Kim, Soo Ji , Seo, Eun Sang, Lee, Sumin , Cho, Eunjin, Chang, Jun , Shim, Byoung-Shik

Mayo Clinic

Vaccines | December 2, 2024 | Volume: 12 | Issue: 12 | Pages: 1354

10.3390/vaccines12121354 | PMID 39772016 Get It

Background/Objectives: Respiratory syncytial virus (RSV) causes symptoms similar to a mild cold for adults, but in case of infants, it causes bronchitis and/or pneumonia, and in some cases, mortality. Mucosal immunity within the respiratory tract includes tissue-resident memory T (TRM) cells and tissue-resident memory B (BRM) cells, which provides rapid and efficient protection against RSV re-infection. Therefore, vaccine strategies should aim to generate mucosal immune responses. However, the interactions between RSV vaccines and mucosal immune responses within the respiratory tract are poorly understood. We evaluated a mucosal immune system following immunization by RSV vaccine with poly-sorbitol transporter (RSV-PST), a nanoparticle adjuvant. Methods: We intranasally immunized the RSV-PST and identified the systemic and mucosal immune responses. Furthermore, we challenged with RSV A2 strain after immunization and investigated the protective effects. Results: Consequently, antigen-specific CD8+ TRM cells were markedly elevated in the lung parenchyma, yet exhibited impaired cytokine expression. In contrast, humoral immunity, with systemic antibody production from serum, but not in the respiratory tract, was significantly increased by RSV-PST immunization. Interestingly, the production of respiratory mucosal antigen-specific IgG after RSV A2 challenge dramatically increased in the bronchoalveolar lavage fluid (BALF) of the RSV-PST immunized group in the presence of FTY720, and the lung-infected RSV titer was significantly lower in this group. Furthermore, after RSV A2 challenge, CD69+ IgG+ BRM cells were significantly increased in lung tissues in the RSV-PST group. Conclusions: The RSV-PST vaccine has protective effects against RSV infection by promoting both systemic and local humoral immunity rather than cellular immunity.
Persistent B Cell–Derived MHC Class II Signaling Is Required for the Optimal Maintenance of Tissue-Resident Helper T Cells
Son, Young Min , Cheon, In Su , Li, Chaofan , Sun, Jie , Sun, Jie , Li, Chaofan

Mayo Clinic

ImmunoHorizons | February 12, 2024 | Volume: 8 | Issue: 2 | Pages: 163-171

10.4049/immunohorizons.2300093 | PMID 38345472 Get It

Abstract Emerging studies have identified the critical roles of tissue-resident memory CD8+ T (TRM) and B (BRM) cells in the protection against mucosal viral infections, but the underlying mechanisms regulating robust development of TRM and BRM cells remain incompletely understood. We have recently shown that tissue-resident helper CD4+ T (TRH) cells, developed following influenza virus infection, function to sustain the optimal maintenance of TRM and BRM cells at the mucosal surface. In this study, we have explored the cellular and molecular cues modulating lung TRH persistence after influenza infection in C57BL/6 mice. We found that TRH cells were colocalized in tertiary lymphoid structures (TLSs) with local B cells. Abolishing TLSs or the depletion of B cells impaired lung TRH cell numbers. Of note, we found that persistent TCR signaling is needed for the maintenance of TRH cells after the clearance of infectious influenza virus. Furthermore, selective ablation of B cell–derived MHC class II resulted in partial reduction of lung TRH cell number after influenza infection. Our findings suggest that the interaction between lung-resident TRH cells and B cells, along with persistent Ag stimulation, is required to maintain TRH cells after respiratory viral infection.
Proximal immune-epithelial progenitor interactions drive chronic tissue sequelae post COVID-19
Sun, Jie , Narasimhan, Harish , Cheon, In Su , Qian, Wei , Li, Chaofan , Goplen, N. , Wu, Yue , Wei, Xiaoqin , Son, Young Min , Yao, Changfu , Canderan, Glenda , Kadl, Alexandra , Cannon, Abigail R. , Young, Samuel , Hannan, Riley, Bingham, Grace C. , Chaudhari, Arka Sen, Pramoonjago, Patcharin , Woodfolk, Judith A. , Li, Chaofan , Goplen, Nicholas P , Wu, Y , Yao, Changfu , Zang, Chongzhi , Sun, Jie , Hu, Shengen Shawn , Parimon, Tanyalak , Fink, Elizabeth , Santos, Gislane de Almeida , Tang, Jinyi , Muehling, Lyndsey M. , Cannon, Abigail, Arish, Mohammad, Sturek, Jeffrey M , Shim, Yun M. , Chen, Peter

Mayo Clinic

No container title available | November 28, 2023 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-3587418/v1 | PMID 38077031 Get It

Abstract The long-term physiological consequences of SARS-CoV-2, termed Post-Acute Sequelae of COVID-19 (PASC), are rapidly evolving into a major public health concern. The underlying cellular and molecular etiology remain poorly defined but growing evidence links PASC to abnormal immune responses and/or poor organ recovery post-infection. Yet, the precise mechanisms driving non-resolving inflammation and impaired tissue repair in the context of PASC remain unclear. With insights from three independent clinical cohorts of PASC patients with abnormal lung function and/or viral infection-mediated pulmonary fibrosis, we established a clinically relevant mouse model of post-viral lung sequelae to investigate the pathophysiology of respiratory PASC. By employing a combination of spatial transcriptomics and imaging, we identified dysregulated proximal interactions between immune cells and epithelial progenitors unique to the fibroproliferation in respiratory PASC but not acute COVID-19 or idiopathic pulmonary fibrosis (IPF). Specifically, we found a central role for lung-resident CD8+ T cell macrophage interactions in maintaining Krt8hi transitional and ectopic Krt5+ basal cell progenitors, thus impairing alveolar regeneration and driving fibrotic sequelae after acute viral pneumonia. Mechanistically, CD8+ T cell derived IFN-γ and TNF stimulated lung macrophages to chronically release IL-1β, resulting in the abnormal accumulation of dysplastic epithelial progenitors and fibrosis. Notably, therapeutic neutralization of IFN-γ and TNF, or IL-1β after the resolution of acute infection resulted in markedly improved alveolar regeneration and restoration of pulmonary function. Together, our findings implicate a dysregulated immune-epithelial progenitor niche in driving respiratory PASC. Moreover, in contrast to other approaches requiring early intervention, we highlight therapeutic strategies to rescue fibrotic disease in the aftermath of respiratory viral infections, addressing the current unmet need in the clinical management of PASC and post-viral disease.
Association of BCG Vaccine Treatment With Death and Dementia in Patients With Non–Muscle-Invasive Bladder Cancer
Weinberg, Marc S. , Zafar, Affan, Magdamo, Colin , Chung, Sun Young , Chou, Wesley H. , Deodhar, Mayuresh, Frendl, Daniel M. , Faustman, Denise L. , Arnold, Steven E. , Vakulenko‐Lagun, Bella , Nayan, Madhur , Feldman, Adam Scott , Das, Sudeshna

Mayo Clinic

JAMA Network Open | May 19, 2023 | Volume: 6 | Issue: 5 | Pages: e2314336

10.1001/jamanetworkopen.2023.14336 | PMID 37204792 Get It

ImportanceThe BCG vaccine—used worldwide to prevent tuberculosis—confers multiple nonspecific beneficial effects, and intravesical BCG vaccine is currently the recommended treatment for non–muscle-invasive bladder cancer (NMIBC). Moreover, BCG vaccine has been hypothesized to reduce the risk of Alzheimer disease and related dementias (ADRD), but previous studies have been limited by sample size, study design, or analyses.ObjectiveTo evaluate whether intravesical BCG vaccine exposure is associated with a decreased incidence of ADRD in a cohort of patients with NMIBC while accounting for death as a competing event.Design, Setting, and ParticipantsThis cohort study was performed in patients aged 50 years or older initially diagnosed with NMIBC between May 28, 1987, and May 6, 2021, treated within the Mass General Brigham health care system. The study included a 15-year follow-up of individuals (BCG vaccine treated or controls) whose condition did not clinically progress to muscle-invasive cancer within 8 weeks and did not have an ADRD diagnosis within the first year after the NMIBC diagnosis. Data analysis was conducted from April 18, 2021, to March 28, 2023.Main Outcomes and MeasuresThe main outcome was time to ADRD onset identified using diagnosis codes and medications. Cause-specific hazard ratios (HRs) were estimated using Cox proportional hazards regression after adjusting for confounders (age, sex, and Charlson Comorbidity Index) using inverse probability scores weighting.ResultsIn this cohort study including 6467 individuals initially diagnosed with NMIBC between 1987 and 2021, 3388 patients underwent BCG vaccine treatment (mean [SD] age, 69.89 [9.28] years; 2605 [76.9%] men) and 3079 served as controls (mean [SD] age, 70.73 [10.00] years; 2176 [70.7%] men). Treatment with BCG vaccine was associated with a lower rate of ADRD (HR, 0.80; 95% CI, 0.69-0.99), with an even lower rate of ADRD in patients aged 70 years or older at the time of BCG vaccine treatment (HR, 0.74; 95% CI, 0.60-0.91). In competing risks analysis, BCG vaccine was associated with a lower risk of ADRD (5-year risk difference, −0.011; 95% CI, −0.019 to −0.003) and a decreased risk of death in patients without an earlier diagnosis of ADRD (5-year risk difference, −0.056; 95% CI, −0.075 to −0.037).Conclusions and RelevanceIn this study, BCG vaccine was associated with a significantly lower rate and risk of ADRD in a cohort of patients with bladder cancer when accounting for death as a competing event. However, the risk differences varied with time.
Respiratory mucosal immunity against SARS-CoV-2 after mRNA vaccination
Tang, Jinyi , Zeng, Cong , Cox, Thomas M, Li, Chaofan , Son, Young Min , Cheon, In Su , Wu, Yue , Taylor, Justin J. , Chakaraborty, Rana, Johnson, Aaron J. , Schiavo, Dante , Utz, James P., Reisenauer, Janani , Midthun, David E. , Mullon, John J., Edell, Eric S. , Alameh, Mohamad‐Gabriel , Borish, Larry , Teague, W. Gerald , Kaplan, Mark H. , Kern, Ryan , Vassallo, Robert , Behl, Supriya, Taylor, Justin J , Chakraborty, Rana , Johnson, Aaron J. , Reisenauer, Janani S , Midthun, David E , Kaplan, Mark H , Weissman, Drew , Kern, R , Hu, Haitao , Vassallo, Robert , Liu, Shan-Lu , Sun, Jie , Tang, J , Li, Chaofan , Behl, Supriya , Chakaraborty, Rana, Liu, Shan-Lu , Sun, Jie

Mayo Clinic

Science Immunology | July 19, 2022 | Volume: 7 | Issue: 76 | Pages: No page available

10.1126/sciimmunol.add4853 | PMID 35857583 Get It

SARS-CoV-2 mRNA vaccination induces robust humoral and cellular immunity in the circulation; however, it is currently unknown whether it elicits effective immune responses in the respiratory tract, particularly against variants of concern (VOCs), including Omicron. We compared the SARS-CoV-2 S–specific total and neutralizing antibody responses, and B and T cell immunity, in the bronchoalveolar lavage fluid (BAL) and blood of COVID-19–vaccinated individuals and hospitalized patients. Vaccinated individuals had significantly lower levels of neutralizing antibody against D614G, Delta (B.1.617.2), and Omicron BA.1.1 in the BAL compared with COVID-19 convalescents despite robust S-specific antibody responses in the blood. Furthermore, mRNA vaccination induced circulating S-specific B and T cell immunity, but in contrast to COVID-19 convalescents, these responses were absent in the BAL of vaccinated individuals. Using a mouse immunization model, we demonstrated that systemic mRNA vaccination alone induced weak respiratory mucosal neutralizing antibody responses, especially against SARS-CoV-2 Omicron BA.1.1 in mice; however, a combination of systemic mRNA vaccination plus mucosal adenovirus-S immunization induced strong neutralizing antibody responses not only against the ancestral virus but also the Omicron BA.1.1 variant. Together, our study supports the contention that the current COVID-19 vaccines are highly effective against severe disease development, likely through recruiting circulating B and T cell responses during reinfection, but offer limited protection against breakthrough infection, especially by the Omicron sublineage. Hence, mucosal booster vaccination is needed to establish robust sterilizing immunity in the respiratory tract against SARS-CoV-2, including infection by the Omicron sublineage and future VOCs.
Circulating autoreactive proteinase 3+ B cells and tolerance checkpoints in ANCA-associated vasculitis
Berti, Alvise , Hillion, Sophie , Hummel, Amber M., Son, Young Min , Chriti, Nedra, Peikert, Tobias, Carmona, Eva M. , Abdulahad, Wayel H. , Heeringa, Peter , Harris, Kristina M. , Clair, E. William St. , Brunetta, Paul , Langford, Carol A. , Kallenberg, Cees G. M., Stone, John H. , Grandi, Guido , Cornec, Divi, Carmona, Eva M , Berti, Alvise , Fervenza, Fernando C. , Merkel, Peter A. , Monach, Paul A. , Seo, Philip , Spiera, Robert , Sun, Jie , Pers, Jacques-Olivier , Specks, Ulrich , Cornec, Divi

Mayo Clinic

JCI Insight | October 7, 2021 | Volume: 6 | Issue: 22 | Pages: No page available

10.1172/jci.insight.150999 | PMID 34618687 Get It

BACKGROUND Little is known about the autoreactive B cells in antineutrophil cytoplasmic antibody–associated (ANCA-associated) vasculitis (AAV). We aimed to investigate tolerance checkpoints of circulating antigen-specific proteinase 3–reactive (PR3 + ) B cells. METHODS Multicolor flow cytometry in combination with bioinformatics and functional in vitro studies were performed on baseline samples of PBMCs from 154 well-characterized participants of the RAVE trial (NCT00104299) with severely active PR3-AAV and myeloperoxidase-AAV (MPO-AAV) and 27 healthy controls (HCs). Clinical data and outcomes from the trial were correlated with PR3 + B cells (total and subsets). RESULTS The frequency of PR3 + B cells among circulating B cells was higher in participants with PR3-AAV (4.77% median [IQR, 3.98%–6.01%]) than in participants with MPO-AAV (3.16% median [IQR, 2.51%–5.22%]) and participants with AAV compared with HCs (1.67% median [IQR, 1.27%–2.16%], P < 0.001 for all comparisons), implying a defective central tolerance checkpoint in patients with AAV. Only PBMCs from participants with PR3-AAV contained PR3 + B cells capable of secreting PR3-ANCA IgG in vitro, proving they were functionally distinct from those of participants with MPO-AAV and HCs. Unsupervised clustering identified subtle subsets of atypical autoreactive PR3 + memory B cells accumulating through the maturation process in patients with PR3-AAV. PR3 + B cells were enriched in the memory B cell compartment of participants with PR3-AAV and were associated with higher serum CXCL13 levels, suggesting an increased germinal center activity. PR3 + B cells correlated with systemic inflammation (C-reactive protein and erythrocyte sedimentation rate, P < 0.05) and complete remission ( P < 0.001). CONCLUSION This study suggests the presence of defective central antigen-independent and peripheral antigen-dependent checkpoints in patients with PR3-AAV, elucidating the selection process of autoreactive B cells. Trial registration ClinicalTrials.gov NCT00104299. Funding The Vasculitis Foundation, the National Institute of Allergy and Infectious Diseases of the NIH, and the Mayo Foundation for Education and Research.
Co-Ordination of Mucosal B Cell and CD8 T Cell Memory by Tissue-Resident CD4 Helper T Cells
Son, Young Min , Son, Y M , Sun, Jie

Mayo Clinic

Cells | September 8, 2021 | Volume: 10 | Issue: 9 | Pages: 2355

10.3390/cells10092355 | PMID 34572004 Get It

Adaptive cellular immunity plays a major role in clearing microbial invasion of mucosal tissues in mammals. Following the clearance of primary pathogens, memory lymphocytes are established both systemically and locally at pathogen entry sites. Recently, resident memory CD8 T and B cells (TRM and BRM respectively), which are parked mainly in non-lymphoid mucosal tissues, were characterized and demonstrated to be essential for protection against secondary microbial invasion. Here we reviewed the current understanding of the cellular and molecular cues regulating CD8 TRM and BRM development, maintenance and function. We focused particularly on elucidating the role of a novel tissue-resident helper T (TRH) cell population in assisting TRM and BRM responses in the respiratory mucosa following viral infection. Finally, we argue that the promotion of TRH responses by future mucosal vaccines would be key to the development of successful universal influenza or coronavirus vaccines, providing long-lasting immunity against a broad spectrum of viral strains.